Status:

COMPLETED

Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA)

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

SMA

Eligibility:

All Genders

6-20 years

Phase:

PHASE2

PHASE3

Brief Summary

This is a multicentric, randomized, double-blind study versus placebo, with two parallel groups treated to evaluate the efficacy and the tolerance of Riluzole in children and young adults (6 to 20 yea...

Detailed Description

ASIRI study should allow to evaluate the efficacy and the tolerance of Riluzole in children and young adults (6 to 20 years of age) with SMA. This is a multicentric, randomized, double-blind study ver...

Eligibility Criteria

Inclusion

  • Patients afflicted with spinal muscular atrophy, type II or III, with genetic defect confirmed.
  • Age between 6 and 20 years old.
  • Score MFM at least 12
  • Negative pregnancy test for women of child-bearing age
  • Signing of an informed consent form, after appropriate information has been provided (if the patient is under 18 years old, both parents are required to sign the form too; otherwise, only her (his) agreement is necessary).

Exclusion

  • Patients already treated with Riluzole
  • Concomitant treatment with: GAPAPENTINE, DEXTROMETHORPHANE, amantadine, any hepatotoxic medication that cannot be stopped, any other experimental product
  • Hepatic insufficiency: SGPT and/or SGOT levels higher than or equal to twice the normal higher limit
  • Renal insufficiency (creatinine above 115 micromoles/l)
  • Severe cardiac insufficiency
  • Current pneumopathy (clinical signs of an acute episode, confirmed by pulmonary X-ray, requiring specific treatment)
  • Pregnancy or nursing for women; non-abstinence or absence of effective contraception for nubile women
  • Any pathology or other circumstance likely to interfere with a regular follow-up
  • No affiliation to any social insurance system

Key Trial Info

Start Date :

January 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2011

Estimated Enrollment :

141 Patients enrolled

Trial Details

Trial ID

NCT00774423

Start Date

January 1 2006

End Date

December 1 2011

Last Update

February 15 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hopital Raymond Poincare

Garches, France, 92380

Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA) | DecenTrialz